Monthly injection may ease anemia treatment for kidney patients
NCT ID NCT07025460
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 4 study tested whether a once-monthly injection of darbepoetin alfa works as well as the standard every-2-week schedule for maintaining healthy hemoglobin levels in people with advanced chronic kidney disease who are not on dialysis. Forty Korean adults completed the 12-week evaluation phase. The goal was to see if the monthly dosing could keep hemoglobin at or above 10.0 g/dL, which would mean fewer injections and less burden for patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
darbepoetin alfa
What this could lead to
If successful, this could offer a more convenient once-monthly injection schedule for managing anemia in chronic kidney disease, potentially improving patient adherence and reducing healthcare visits.
What could go wrong
This is a small, single-arm study in a specific Korean population, so results may not apply broadly. The trial is already complete, and while it showed non-inferiority, larger studies would be needed to confirm safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institutional Review Board, Gangnam Severance Hospitial Yonsei University College of Medicine
Seoul, South Korea